2021
DOI: 10.1371/journal.pone.0248535
|View full text |Cite
|
Sign up to set email alerts
|

Prediction of COPD risk accounting for time-varying smoking exposures

Abstract: Rationale Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the United States. Studies have primarily assessed the relationship between smoking on COPD risk focusing on summary measures, like smoking status. Objective Develop a COPD risk prediction model incorporating individual time-varying smoking exposures. Methods The Nurses’ Health Study (N = 86,711) and the Health Professionals Follow-up Study (N = 39,817) data was used to develop a COPD risk prediction model. Data … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
23
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
2
1

Relationship

1
6

Authors

Journals

citations
Cited by 22 publications
(24 citation statements)
references
References 38 publications
0
23
0
1
Order By: Relevance
“…[13][14][15][16] While previous studies typically included some measure of current smoking status, none controlled for smoking duration or intensity. High levels of smoking exposure are needed for COPD to develop, 10,31,32 and not controlling for this exposure may potentially conflate the effect of ENDS use with individual smoking histories. In our study, once we adjusted for time-varying smoking status and baseline smoking history, measured as pack-years, ENDS use was no longer associated with incident COPD.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…[13][14][15][16] While previous studies typically included some measure of current smoking status, none controlled for smoking duration or intensity. High levels of smoking exposure are needed for COPD to develop, 10,31,32 and not controlling for this exposure may potentially conflate the effect of ENDS use with individual smoking histories. In our study, once we adjusted for time-varying smoking status and baseline smoking history, measured as pack-years, ENDS use was no longer associated with incident COPD.…”
Section: Discussionmentioning
confidence: 99%
“…Similar to other research, 8 we also found that time-varying second-hand smoke exposure was predictive of self-reported diagnosed incident COPD. It has been argued that more detailed information on smoking histories are needed to improve the predictive accuracy of COPD risk models, 10 and incorporating measures of both direct and indirect smoking exposure are important to more fully understand the smoking-COPD relationship.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…For this reason, considering the burden of COPD exacerbations in terms both of mortality and morbidity, regular treatment with triple therapy should be started as soon as the diagnosis of COPD is formulated and not after the development of a severe COPD exacerbation leading to hospitalisation or following a pre-determined number of COPD exacerbations per year and/or fall in FEV1 percent predicted 1 . Administration of theophylline in patients with stable COPD decreases the dyspnoea and, in some cases, increases tolerance to exercise 47 . A one-year RCT 87 supports the use of low-dose regular use of theophylline, in addition to the triple inhalation therapy, but not with ICS alone or with double inhaled combination such as ICS/LABA or LABA/LAMA in the prevention of COPD exacerbations, including hospital admissions; however, effectiveness of regular use of low-dose of theophylline is still debated 88 .…”
Section: Management Of Stable Copd Based On Symptoms Lung Function An...mentioning
confidence: 99%
“…There is still insufficient evidence to target the treatment of stable COPD patients differently according to their gender [44][45][46] . The prescription of an as-needed rescue formulation of an inhaled short-acting muscarinic antagonist (SAMA) and/or a short-acting b₂-agonist (SABA) is indicated for all stable COPD patients to help in the control of respiratory symptoms, particularly exertion dyspnoea 47 .…”
Section: General Drug Treatment Recommendations For Stable Copd Patientsmentioning
confidence: 99%